Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium

被引：0

作者：

C L Pearce

A M Near

D J Van Den Berg

S J Ramus

A Gentry-Maharaj

U Menon

S A Gayther

A R Anderson

C K Edlund

A H Wu

X Chen

J Beesley

P M Webb

S K Holt

C Chen

J A Doherty

M A Rossing

A S Whittemore

V McGuire

R A DiCioccio

M T Goodman

G Lurie

M E Carney

L R Wilkens

R B Ness

K B Moysich

R Edwards

E Jennison

S K Kjaer

E Hogdall

C K Hogdall

E L Goode

T A Sellers

R A Vierkant

J C Cunningham

J M Schildkraut

A Berchuck

P G Moorman

E S Iversen

D W Cramer

K L Terry

A F Vitonis

L Titus-Ernstoff

H Song

P D P Pharoah

A B Spurdle

H Anton-Culver

A Ziogas

W Brewster

V Galitovskiy

机构：

[1] Keck School of Medicine,Department of Preventive Medicine

[2] University of Southern California,Department of Epidemiology

[3] University of Michigan School of Public Health,Division of Public Health Sciences

[4] Keck School of Medicine,Department of Health Research and Policy, Division of Epidemiology

[5] University of Southern California,Department of Cancer Genetics

[6] Gynaecological Cancer Research Laboratories,Department of Cancer Prevention and Control

[7] UCL EGA Institute for Women's Health,Department of OB/GYN/RS

[8] University College London,Department of Virus

[9] UCL EGA Institute for Women's Health,Division of Gynecologic Oncology

[10] Gynaecological Cancer Research Centre,Department of Statistical Sciences

[11] The Queensland Institute of Medical Research,Department of Community and Family Medicine and of Pediatrics

[12] Post Office Royal Brisbane Hospital,Department of Oncology

[13] Herston,Department of Epidemiology

[14] Brisbane,Department of OB/GYN

[15] QLD 4029,undefined

[16] Australia,undefined

[17] Epidemiology Program,undefined

[18] Fred Hutchinson Cancer Research Center,undefined

[19] Stanford University School of Medicine,undefined

[20] Roswell Park Cancer Institute,undefined

[21] Cancer Research Center,undefined

[22] University of Hawaii,undefined

[23] The University of Texas School of Public Health,undefined

[24] Roswell Park Cancer Institute,undefined

[25] Magee-Women's Hospital,undefined

[26] University of Pittsburgh Medical Center,undefined

[27] Gynecologic Oncologists of Northeast Ohio,undefined

[28] Hormones and Cancer,undefined

[29] Institute of Cancer Epidemiology,undefined

[30] Danish Cancer Society,undefined

[31] 2100 Copenhagen,undefined

[32] Denmark,undefined

[33] Gynaecologic Clinic,undefined

[34] Juliane Marie Centre,undefined

[35] Rigshospitalet,undefined

[36] University of Copenhagen,undefined

[37] 2100 Copenhagen,undefined

[38] Denmark,undefined

[39] Mayo Clinic College of Medicine,undefined

[40] H. Lee Moffitt Cancer Center and Research Institute,undefined

[41] MRC CANCONT,undefined

[42] Tampa,undefined

[43] FL,undefined

[44] 33612,undefined

[45] USA,undefined

[46] Cancer Prevention and Control Research Program,undefined

[47] Duke University Medical Center,undefined

[48] Duke University Medical Center,undefined

[49] Duke University,undefined

[50] Brigham and Women's Hospital,undefined

来源：

British Journal of Cancer | 2009年 / 100卷

关键词：

ovarian cancer; genetic susceptibility; oestrogen metabolism; CYP3A4; pooled-analyses;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The search for genetic variants associated with ovarian cancer risk has focused on pathways including sex steroid hormones, DNA repair, and cell cycle control. The Ovarian Cancer Association Consortium (OCAC) identified 10 single-nucleotide polymorphisms (SNPs) in genes in these pathways, which had been genotyped by Consortium members and a pooled analysis of these data was conducted. Three of the 10 SNPs showed evidence of an association with ovarian cancer at P⩽0.10 in a log-additive model: rs2740574 in CYP3A4 (P=0.011), rs1805386 in LIG4 (P=0.007), and rs3218536 in XRCC2 (P=0.095). Additional genotyping in other OCAC studies was undertaken and only the variant in CYP3A4, rs2740574, continued to show an association in the replication data among homozygous carriers: ORhomozygous(hom)=2.50 (95% CI 0.54-11.57, P=0.24) with 1406 cases and 2827 controls. Overall, in the combined data the odds ratio was 2.81 among carriers of two copies of the minor allele (95% CI 1.20–6.56, P=0.017, phet across studies=0.42) with 1969 cases and 3491 controls. There was no association among heterozygous carriers. CYP3A4 encodes a key enzyme in oestrogen metabolism and our finding between rs2740574 and risk of ovarian cancer suggests that this pathway may be involved in ovarian carcinogenesis. Additional follow-up is warranted.

引用

页码：412 / 420

页数：8

共 50 条

[21] Endometriosis and highly fatal ovarian cancer - evidence from the ovarian cancer association consortium
Alsulimani, A.
Ness, R.
Joseph, J.
Cannioto, R.
Moysich, K.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 : 54 - 54
[22] Ovarian Cancer Association Consortium analysis of seven candidate ovarian cancer susceptibility polymorphisms
Ramus, S. J.
Vierkant, R. A.
Jonhatty, S.
Schildkraut, J. M.
Pharoah, P. D.
Chenevix-Trench, G.
Pearce, C. L.
Berchuck, A.
Goode, E. L.
GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S29 - S30
[23] Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium
Johnatty, Sharon E.
Beesley, Jonathan
Chen, Xiaoqing
Spurdle, Amanda B.
DeFazio, Anna
Webb, Penelope M.
Goode, Ellen L.
Rider, David N.
Vierkant, Robert A.
Anderson, Stephanie
Wu, Anna H.
Pike, Malcolm
Van Den Berg, David
Moysich, Kirsten
Ness, Roberta
Doherty, Jennifer
Rossing, Mary-Anne
Pearce, Celeste Leigh
Chenevix-Trench, Georgia
TWIN RESEARCH AND HUMAN GENETICS, 2009, 12 (03) : 269 - 275
[24] Prediagnostic physical inactivity and epithelial ovarian cancer risk and mortality: Evidence from the Ovarian Cancer Association Consortium.
Cannioto, Rikki A.
LaMonte, Michael
Moysich, Kirsten B.
CLINICAL CANCER RESEARCH, 2016, 22
[25] Impact of physical inactivity on risk of developing highly fatal ovarian cancer: Evidence from the Ovarian Cancer Association Consortium
Almohanna, H.
Joseph, J. M.
Cannioto, R. A.
Mayor, P.
Starbuck, K.
AlSulimani, A.
Mongiovi, J.
Minlikeeva, A. N.
Moysich, K. B.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 219 - 219
[26] Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC)
Bolton, K. L.
Ganda, C.
Berchuck, A.
Pharaoh, P. D. P.
Gayther, S. A.
JOURNAL OF INTERNAL MEDICINE, 2012, 271 (04) : 366 - 378
[27] Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Nagle, C. M.
Dixon, S. C.
Jensen, A.
Kjaer, S. K.
Modugno, F.
deFazio, A.
Fereday, S.
Hung, J.
Johnatty, S. E.
Fasching, P. A.
Beckmann, M. W.
Lambrechts, D.
Vergote, I.
Van Nieuwenhuysen, E.
Lambrechts, S.
Risch, H. A.
Rossing, M. A.
Doherty, J. A.
Wicklund, K. G.
Chang-Claude, J.
Goodman, M. T.
Ness, R. B.
Moysich, K.
Heitz, F.
du Bois, A.
Harter, P.
Schwaab, I.
Matsuo, K.
Hosono, S.
Goode, E. L.
Vierkant, R. A.
Larson, M. C.
Fridley, B. L.
Hogdall, C.
Schildkraut, J. M.
Weber, R. P.
Cramer, D. W.
Terry, K. L.
Bandera, E. V.
Paddock, L.
Rodriguez-Rodriguez, L.
Wentzensen, N.
Yang, H. P.
Brinton, L. A.
Lissowska, J.
Hogdall, E.
Lundvall, L.
Whittemore, A.
McGuire, V.
Sieh, W.
BRITISH JOURNAL OF CANCER, 2015, 113 (05) : 817 - 826
[28] History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Minlikeeva, Albina N.
Freudenheim, Jo L.
Eng, Kevin H.
Cannioto, Rikki A.
Friel, Grace
Szender, J. Brian
Segal, Brahm
Odunsi, Kunle
Mayor, Paul
Diergaarde, Brenda
Zsiros, Emese
Kelemen, Linda E.
Kobel, Martin
Steed, Helen
deFazio, Anna
Jordan, Susan J.
Fasching, Peter A.
Beckmann, Matthias W.
Risch, Harvey A.
Rossing, Mary Anne
Doherty, Jennifer A.
Chang-Claude, Jenny
Goodman, Marc T.
Doerk, Thilo
Edwards, Robert
Modugno, Francesmary
Ness, Roberta B.
Matsuo, Keitaro
Mizuno, Mika
Karlan, Beth Y.
Goode, Ellen L.
Kjaer, Susanne K.
Hogdall, Estrid
Schildkraut, Joellen M.
Terry, Kathryn L.
Cramer, Daniel W.
Bandera, Elisa V.
Paddock, Lisa E.
Kiemeney, Lambertus A.
Massuger, Leon F. A. G.
Sutphen, Rebecca
Anton-Culver, Hoda
Ziogas, Argyrios
Menon, Usha
Gayther, Simon A.
Ramus, Susan J.
Gentry-Maharaj, Aleksandra
Pearce, Celeste L.
Wu, Anna H.
Kupryjanczyk, Jolanta
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (09) : 1470 - 1473
[29] Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
C M Nagle
S C Dixon
A Jensen
S K Kjaer
F Modugno
A deFazio
S Fereday
J Hung
S E Johnatty
P A Fasching
M W Beckmann
D Lambrechts
I Vergote
E Van Nieuwenhuysen
S Lambrechts
H A Risch
M A Rossing
J A Doherty
K G Wicklund
J Chang-Claude
M T Goodman
R B Ness
K Moysich
F Heitz
A du Bois
P Harter
I Schwaab
K Matsuo
S Hosono
E L Goode
R A Vierkant
M C Larson
B L Fridley
C Høgdall
J M Schildkraut
R P Weber
D W Cramer
K L Terry
E V Bandera
L Paddock
L Rodriguez-Rodriguez
N Wentzensen
H P Yang
L A Brinton
J Lissowska
E Høgdall
L Lundvall
A Whittemore
V McGuire
W Sieh
British Journal of Cancer, 2015, 113 : 817 - 826
[30] Use of progestin-only injectable contraceptive is associated with reduced risk of ovarian cancer in the Ovarian Cancer Association Consortium.
Minh Tung Phung
Webb, Penelope M.
Doherty, Jennifer Anne
Harris, Holly R.
Thompson, Pamela J.
Goodman, Marc T.
Moysich, Kirsten
Modugno, Francesmary
Ness, Roberta B.
Schildkraut, Joellen M.
Berchuck, Andrew
Cramer, Daniel W.
Terry, Kathryn L.
Titus, Linda
Lee, Alice W.
Pike, Malcolm C.
Wu, Anna H.
Pearce, Celeste Leigh
CLINICAL CANCER RESEARCH, 2020, 26 (13) : 99 - 100

← 1 2 3 4 5 →